Nitrolingual Pumpspray is a drug owned by Pohl Boskamp. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 12, 2029. Details of Nitrolingual Pumpspray's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7872049 | Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate |
Mar, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nitrolingual Pumpspray's patents.
Latest Legal Activities on Nitrolingual Pumpspray's Patents
Given below is the list of recent legal activities going on the following patents of Nitrolingual Pumpspray.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Jul, 2022 | US7872049 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jul, 2018 | US7872049 |
| Recordation of Patent Grant Mailed Critical | 18 Jan, 2011 | US7872049 |
| Patent Issue Date Used in PTA Calculation Critical | 18 Jan, 2011 | US7872049 |
| Issue Notification Mailed Critical | 28 Dec, 2010 | US7872049 |
| Dispatch to FDC | 22 Dec, 2010 | US7872049 |
| Application Is Considered Ready for Issue Critical | 16 Dec, 2010 | US7872049 |
| Issue Fee Payment Received Critical | 15 Dec, 2010 | US7872049 |
| Issue Fee Payment Verified Critical | 15 Dec, 2010 | US7872049 |
| Mail Notice of Allowance Critical | 07 Dec, 2010 | US7872049 |
US patents provide insights into the exclusivity only within the United States, but Nitrolingual Pumpspray is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nitrolingual Pumpspray's family patents as well as insights into ongoing legal events on those patents.
Nitrolingual Pumpspray's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nitrolingual Pumpspray's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 12, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nitrolingual Pumpspray Generic API suppliers:
Nitroglycerin is the generic name for the brand Nitrolingual Pumpspray. 26 different companies have already filed for the generic of Nitrolingual Pumpspray, with Mylan Technologies having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Nitrolingual Pumpspray's generic
How can I launch a generic of Nitrolingual Pumpspray before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Nitrolingual Pumpspray's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Nitrolingual Pumpspray's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Nitrolingual Pumpspray -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 400 mcg/spray, 4.9 g and 12 g bottles | 17 Apr, 2012 | 1 | 20 Sep, 2013 | 14 Mar, 2028 | Eligible |
Alternative Brands for Nitrolingual Pumpspray
Nitrolingual Pumpspray which is used for treating angina pectoris., has several other brand drugs using the same active ingredient (Nitroglycerin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Nitroglycerin, Nitrolingual Pumpspray's active ingredient. Check the complete list of approved generic manufacturers for Nitrolingual Pumpspray
About Nitrolingual Pumpspray
Nitrolingual Pumpspray is a drug owned by Pohl Boskamp. It is used for treating angina pectoris. Nitrolingual Pumpspray uses Nitroglycerin as an active ingredient. Nitrolingual Pumpspray was launched by Pohl Boskamp in 1985.
Approval Date:
Nitrolingual Pumpspray was approved by FDA for market use on 31 October, 1985.
Active Ingredient:
Nitrolingual Pumpspray uses Nitroglycerin as the active ingredient. Check out other Drugs and Companies using Nitroglycerin ingredient
Treatment:
Nitrolingual Pumpspray is used for treating angina pectoris.
Dosage:
Nitrolingual Pumpspray is available in spray, metered form for sublingual use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.4MG/SPRAY | SPRAY, METERED | Prescription | SUBLINGUAL |